Sustained complete molecular remission after imatinib discontinuation in children with chronic myeloid leukemia

Area of Science:

• Pediatric Hematology
• Oncology
• Clinical Research

Background:

• Complete molecular response (CMR) is achievable in adults with chronic myeloid leukemia (CML) on imatinib therapy.
• Approximately 40% of adults maintain CMR after imatinib discontinuation.
• Data on imatinib discontinuation in pediatric CML patients are limited.

Purpose of the Study:

• To investigate the feasibility of imatinib discontinuation in children with CML.
• To assess disease status in pediatric patients achieving CMR after imatinib cessation.
• To evaluate the potential for minimizing imatinib exposure and side effects in low-risk children.

Main Methods:

• Case study of two pediatric patients with CML in sustained CMR.
• Monitoring of disease levels via RNA transcript and genomic DNA.
• Assessment of patient risk stratification based on adult criteria.

Main Results:

• Two pediatric CML patients maintained CMR for 48 and 19 months post-imatinib discontinuation.
• Both patients exhibited low-level, fluctuating disease at molecular levels.
• Patients were classified as low-risk according to established adult criteria.

Conclusions:

• Imatinib discontinuation may be a viable option for select low-risk pediatric CML patients.
• Clinical trials are warranted to further evaluate treatment cessation in this population.
• Close monitoring is essential to manage potential molecular relapses and minimize long-term imatinib exposure.